You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: NCI

    Project Summary/Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which PDAC is diagnosed and a lack of effective targeted therapies. While the field of immunotherapy has significantly increased overall survival in some malignancies, they have not translated to PDAC. The long-term goal of this research ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. F plus G RSV VLP Vaccine for Improved Safety and Efficacy

    SBC: RAZI PHARMA LLC            Topic: NIAID

    Project Summary Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants and young children worldwide. Since infection induces only partial protection, it causes repeat infection and disease throughout life. Though a high priority for vaccine development no vaccine is yet available. The lack of success in developing a vaccine suggests novel strateg ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of novel pharmacotherapies for AUD

    SBC: NEUROEPIGENIX, LLC            Topic: 150

    Project Summary The overall goal of this proposal is to characterize a lead compound with a novel mode of action (MOA) that reduces both stress- and dependence-related alcohol drinking in a preclinical model of Alcohol Use Disorder (AUD). AUD is a major problem in the U.S. as approximately 13.9% of adults meet AUD criteria per year. The annual economic burden of AUD is estimated at andgt;$200 bill ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development of the GlycoHCCTyper for the early detection of HCC

    SBC: GLYCOPATH INC            Topic: 102

    Alterations in glycosylation have long been associated with the development and progression of many types of chronic and acute diseases. Our group (Mehta) was one of the first to perform glycan analysis in serum and perform proteomics on specific glycoforms (glycoproteomics). Using such methods, we identified a number of serum glycoproteins with altered glycosylation in hepatocellular carcinoma, a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Neural Stem Cell Extracellular Vesicle Treatment for Traumatic Brain Injury

    SBC: ARUNA BIO, INC.            Topic: NINDS

    Project Summary/AbstractTraumatic brain injury (TBI) is a universal health concern and is known as a “silent epidemic”. Each year in America, 2.53 million patients visit the emergency department after suffering a TBI of which 56,800 die and over 288,000 require hospitalization, rehabilitation programs, and long-term supportive care. Although the primary TBI event is typically acute, subsequent ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Colon cancer prevention with non-systemic PDE5 inhibitors

    SBC: Targut Biotechnologies Inc.            Topic: 102

    Approximately 50,000 people will die from colorectal cancer (CRC) in the United States this year due to the late stage at diagnosis where treatments are largely ineffective. Primary prevention of CRC is therefore very important for high-risk patients. Chemoprevention agents are needed for CRC but nothing has been approved for this purpose. Extensive preclinical and epidemiological evidence show gr ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the UValidate platform for the profiling of topically applied chemical agents.

    SBC: AMELIA TECHNOLOGIES LLC            Topic: R

    Project Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer

    SBC: PAZ PHARMACEUTICALS LLC            Topic: NCI

    Summary Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the U.S. with a 5-year survival rate of andlt;9%. The poor prognosis is partially due to resistance to standard of care treatments including gemcitabine (Gem) and Gem+nab-paclitaxel (n-PTX). The transcription factors HIF-1α and c-MYC are at the center of the mechanisms producing Gem and n-PTX resistance ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting AML Mitochondria by Ceramide

    SBC: LIPO-IMMUNO TECH LLC            Topic: 102

    SUMMARY This proposalandapos;s long-term objective is to develop a mechanism-based therapeutic drug for the treatment of human acute myeloid leukemias (AML), which are among the deadliest cancers in the United States. Despite some advances in treatment, survival for AML has not improved significantly in decades, with rare exceptions for specific subclasses. While targeted therapies with FLT3, IDH, ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Investigation of chitosan-supported silver as a safe and effective broad-spectrum antimicrobial textile finish

    SBC: CHITOZAN HEALTH LLC            Topic: NIAID

    PROJECT SUMMARY Maximum of 30 lines of textMinimum of ½” marginsFont size 11 pts or greater The overall research goal of the proposed work is to test the antimicrobial activity and durability of a chitosan-supported silver-based textile finish for incorporation into hospital privacy curtains. Furthermore, successful development of this textile finish for privacy curtains would set the foundatio ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government